[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urethral-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urethral-cancer":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,66,136,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100602476","destiny-pantumour04-100602476",false,"NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","ALL","18 Years","130 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","RECRUITING","2026-06-26",{"date":56,"type":57},"2026-06-29","ACTUAL",{"date":59,"type":57},"2025-09-18",{"date":61,"type":22},"2028-03-30",{"name":63,"class":64},"AstraZeneca","INDUSTRY",17,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":78,"studyType":23,"phases":4,"briefSummary":79,"conditions":80,"keywords":116,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":77,"type":22},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[41,49,81,31,82,83,84,85,27,86,87,88,89,35,90,91,92,93,28,94,95,42,47,96,50,97,98,99,100,101,102,103,104,44,105,106,107,108,109,110,36,45,111,112,40,30,51,113,114,115],"Lung Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Kidney Cancer","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[41,49,117,118,119,120,121,122,123,124,109,125,114,115],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":56,"type":57},{"date":129,"type":57},"2013-11-01",{"date":131,"type":22},"2099-12",{"name":133,"class":134},"University of Nebraska","OTHER",42,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":145,"phases":146,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100507526","phase-1-64cu-grip-b-in-patients-with-advanced-malignancies-100507526","NCT05888532","64Cu-GRIP B in Patients With Advanced Malignancies","A First-in-Human, Phase I\u002FII PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Malignancies","Inclusion Criteria:\n\n1. Disease characteristics by cohort, as defined by:\n\n   Cohort A:\n   * Histologically-confirmed metastatic solid tumor malignancy (3 Male, 3 Female)\n   * Locally advanced or metastatic disease on conventional imaging\n\n   Cohort B:\n   * Histologically-confirmed metastatic renal cell carcinoma (any histologic sub-type) or urothelial carcinoma\n   * Locally advanced or metastatic disease on conventional imaging\n\n   Cohort C:\n   * Histologically-confirmed prostate adenocarcinoma\n   * Metastatic castration resistant prostate cancer by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria\n2. Planned treatment with immune checkpoint inhibitor (Cohorts B and C only)\n3. Willing to undergo paired tumor biopsies and has safely accessible bone or soft tissue lesion (Cohorts B and C only)\n4. The subject is able and willing to comply with study procedures and provide signed and dated informed consent.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n6. Age 18 years or older at the time of study entry.\n7. Adequate organ function, as defined by:\n\n   * Serum creatinine \\\u003C= 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \\> 60 mL\u002Fmin\n   * Total bilirubin \\\u003C= 1.5 x ULN (\\\u003C 3 x ULN in patients with documented or suspected Gilbert's).\n   * Hemoglobin \\>= 8.0 g\u002FdL\n   * Platelet count \\>= 75,000\u002Fmicroliter\n   * Absolute neutrophil count ≥ 1000\u002Fmicroliter\n8. Patients must not be pregnant or breast feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of PET Imaging scan. Effective contraception (men and women) must be used in subjects of child-bearing potential.\n\nExclusion Criteria:\n\n1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.\n2. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.\n3. Is currently pregnant or breastfeeding.",{"count":144,"type":22},91,"INTERVENTIONAL",[147,148],"PHASE1","PHASE2","This phase I\u002FII clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors that are more likely to respond to treatment. The study population is focused on genitourinary (GU) malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors. The information gained from this trial may allow researchers to develop future trials where 64Cu-GRIP B PET may serve as a biomarker to monitor early response to immunomodulatory therapies which are used to stimulate or suppress the immune system and may help the body fight cancer.",[42,151,50,152,153,154],"Renal Cancer","Advanced Solid Tumor","Metastatic Castration-resistant Prostate Cancer","Solid Tumor, Adult",[156,157,158],"Imaging Study","Radiotracer","Granzyme B","2026-03-13",{"date":161,"type":57},"2026-03-17",{"date":163,"type":57},"2023-05-25",{"date":165,"type":22},"2027-01-31",{"name":167,"class":134},"Rahul Aggarwal",1,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":145,"phases":178,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":168},"100508357","a-novel-imaging-protocol-in-use-to-identify-lymph-nodes-and-organs-of-interest-100508357","NCT05899361","A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest","A Pilot Study of a Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest for Surgical Dissection Within Urologic Regions of Interest.","Inclusion Criteria:\n\n* Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management\n* Subjects aged ≥ 18 years. Selected patients must have a confirmed or suspected diagnosis of disease in urologic regions of interest, with scheduled confirmatory surgical biopsy.\n* Subjects must have had either of the following scans: CT, PET or MR of acceptable quality at Brigham and Women's Hospital within the past year.\n* Subjects must also be scheduled to undergo lymph node dissection for a urologic cancer or organ removal of any of the following urologic regions of interest: Bladder, Prostate, Testicle, Ureter, Kidney, Urethra, Penis, and Scrotum\n* Subjects must also be scheduled to undergo a laparoscopic lymph node dissection and\u002For a urologic organ removal within any OR at BWH.\n\nExclusion Criteria:\n\n* Severely impaired renal function with an EGFR \\\u003C 30 mL\u002Fmin\u002Fbody surface area\n* Evidence of any significant, uncontrolled comorbid condition that could affect compliance with the protocol or interpretation of the results, which is to be judged at the discretion of the PI\n* History of hypersensitivity or other contraindication to contrast media\n* Contraindication to general anesthesia\n* Pregnancy",{"count":177,"type":22},10,[179],"NA","This research study is a pilot clinical trial, which hypothesizes that the combination of electromagnetic tracking in conjunction with laparoscope imaging and ultrasound probe imaging will aid in reducing the complexity of both laparoscopic lymphadenectomy and\u002For organ removal in patients with a confirmed diagnosis of cancer in urologic regions of interest (Bladder, Prostate, Testicular, Kidney, Urethral, and Penis), by resulting in better visualization and more accurate localization of certain areas in the diseased organ or the diseased lymph node, and allowing for improved surgical and patient outcomes, fewer complications and better clinician performance.",[182,183,28,42,47,94,50,95],"Urologic Cancer","Urologic Neoplasms",[185,182,183,28,42,47,94,50,95],"Lymph Node Dissection","2023-10-23",{"date":188,"type":57},"2023-10-24",{"date":190,"type":57},"2023-08-30",{"date":192,"type":22},"2026-12-25",{"name":194,"class":134},"Dana-Farber Cancer Institute"]